Conessine (Steroidal Alkaloid · Amoebicidal · Kutaj · IBS Diarrhoea)
| Compound | Conessine |
| Chemical class | Alkaloid — Steroidal Alkaloid (Pregnane-type; N,N-dimethylconanine) |
| CAS | 546-06-5 |
| Primary source | Holarrhena pubescens (Kutaj / Indrajav / Conessi bark), Holarrhena antidysenterica |
| Key applications | Amoebicidal (dysentery), anti-inflammatory, antiprotozoal, antidiarrhoeal |
| Claim strength | Moderate |
| Typical form | Conessi bark extract standardised to conessine; Kutaj/Indrajav extract (Ayurvedic) |
| Buy from Herbuno |
Name origin: From Conessi — the common name for Holarrhena pubescens bark in traditional Indian commerce. Conessine is the primary steroidal alkaloid of Conessi/Kutaj bark — a pregnane-type steroid with a tertiary amine (N,N-dimethyl group). Unlike solanine and solasodine which are food-safety contexts, conessine has a well-established and highly specific therapeutic application: treatment of Entamoeba histolytica dysentery. Traditional use: Kutaj (Holarrhena pubescens/antidysenterica) is one of the most important medicinal plants in Ayurveda for intestinal diseases — specifically for Pravahika (amoebic dysentery, mucous colitis) and IBS with diarrhoea. The Sanskrit name Kutaj means “born in a pot/gourd” (referring to its habitat). The bark and seeds (Indrajav) have been used for dysentery for at least 2,500 years across South Asian medicine. Conessine’s specific amoebicidal activity was identified in the 1930s and was used as a pharmaceutical antiamoebic drug before the widespread availability of metronidazole. Research trajectory: Conessine has well-established amoebicidal activity, anti-inflammatory effects, and antidiarrhoeal properties. It was used as a pharmaceutical drug (Holarrhena alkaloids, primarily in India) before being replaced by more convenient antiprotozoals. The compound also inhibits histamine H3 receptors — an interesting pharmacological property for neurological research contexts. Commercial source: Conessi Bark Extract Powder and Indrajav Liquid Extract from Herbuno. See sourcing options below.
Evidence for Conessine Applications
Amoebicidal — Entamoeba histolytica: Conessine has specific and potent activity against Entamoeba histolytica (the causative agent of amoebic dysentery and amoebic liver abscess) in vitro and in animal models. Mechanism: disrupts amoeba membrane integrity and inhibits cysteine protease activity (essential amoeba digestive enzymes). Pre-metronidazole, Holarrhena alkaloid preparations were used clinically for amoebic dysentery in India with documented efficacy. Claim strength: Moderate (historical pharmaceutical use; mechanistic; limited modern clinical trials vs metronidazole).
Anti-inflammatory and antidiarrhoeal: Conessine inhibits NF-κB, reduces intestinal smooth muscle spasm, and decreases intestinal secretion in animal diarrhoea models. These mechanisms complement amoebicidal activity for comprehensive management of dysenteric symptoms. Consistent with traditional Ayurvedic Kutaj use for IBS with predominant diarrhoea. Claim strength: Moderate.
H3 receptor antagonism: Conessine is a potent histamine H3 receptor antagonist — with IC50 values similar to pharmaceutical H3 antagonists under development for Alzheimer’s disease, ADHD, and narcolepsy. This mechanism makes conessine scientifically interesting for neurological applications, though no human clinical development has occurred for this indication. Claim strength: Moderate (in vitro pharmacology; no human CNS data).
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Traditional Ayurvedic Kutaj doses for dysentery: bark decoction 3–6 g per dose; Kutajghan Vati (concentrated tablet) containing standardised Holarrhena extract at 250–500 mg per dose 2–3×/day. Conessine content in Conessi bark: typically 0.5–2% alkaloids (primarily conessine). For supplement formulations targeting gut health and IBS diarrhoea, Conessi bark extract at 200–500 mg/day standardised to conessine content is appropriate. Request HPLC conessine content alongside total alkaloid yield on CoA. Conessine is well-absorbed orally and has reasonable bioavailability. Kutaj is approved in AYUSH/traditional medicine frameworks for GI applications in India.
Frequently Asked Questions — Conessine
Is conessine the same as metronidazole for amoebic dysentery?
No — conessine and metronidazole are both amoebicidal but mechanistically distinct. Metronidazole (pharmaceutical nitroimidazole) produces reactive nitro radical anions that damage amoeba DNA — it is the current standard of care with well-defined dosing and resistance patterns. Conessine disrupts amoeba membrane integrity and inhibits cysteine proteases — a different mechanism. Conessine is not used as first-line therapy for amoebic dysentery in modern clinical settings but remains relevant in traditional medicine contexts and as a supplement for IBS diarrhoea and gut antimicrobial support, where amoeba-specific claims are not being made.
What is the difference between Kutaj (Holarrhena) and Indrajav?
Kutaj refers to the bark of Holarrhena pubescens (and the closely related H. antidysenterica). Indrajav refers specifically to the seeds of the same plant. Both bark and seeds contain conessine and related alkaloids — the bark is more commonly used in Ayurvedic traditional preparations (Kutajghan, Kutajarista), while the seeds (Indrajav) are used in specific anti-diarrhoeal formulations. The alkaloid profile is similar but not identical between bark and seed preparations.
Can conessine be used for IBS with diarrhoea?
Yes — the antidiarrhoeal, anti-inflammatory, and antispasmodic properties of Conessi bark/Kutaj align well with IBS with predominant diarrhoea (IBS-D) management. Traditional Ayurvedic use of Kutaj for mucous colitis and IBS-D is well-documented. For supplement positioning, “supports healthy bowel transit and GI comfort” or “traditionally used for digestive health and bowel regularity” are appropriate claim framings. Specific antiamoebic claims require evidence from clinical contexts.
Is conessine’s H3 receptor antagonism clinically relevant?
Histamine H3 receptors are presynaptic receptors modulating neurotransmitter release (histamine, acetylcholine, dopamine) in the CNS. H3 antagonists are under pharmaceutical investigation for Alzheimer’s disease (pitolisant is approved for narcolepsy and has H3 antagonist mechanism). Conessine’s H3 receptor antagonism is a scientifically interesting pharmacological property — it positions conessine as a potential neurological active beyond its GI applications. Human CNS-relevant clinical data for conessine are not yet available.
Related compounds: Tomatine, Solasodine, Andrographolide, Glycyrrhizin
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery